Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsFelix Knauf, MD
Assistant Professor AdjunctAbout
Research
Publications
2025
SLC26A1 directs sulfate homeostasis in health and disease
Pitzken F, Köttgen A, Aronson P, Knauf F. SLC26A1 directs sulfate homeostasis in health and disease. Current Opinion In Nephrology & Hypertension 2025, 35: 126-132. PMID: 41056011, DOI: 10.1097/mnh.0000000000001123.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsOxalate homeostasisMouse modelKidney stone diseaseSulfate homeostasisStone diseaseOxalate transportTissue-specific gene deletionAcetaminophen-induced liver injuryKnockout mouse modelSulfation of proteoglycansDamaging variantsClinical outcomesMusculoskeletal abnormalitiesLiver injuryGene deletionHuman diseasesDisease pathogenesisSkeletal integrityAssociated diseasesCell functionSlc26a1DiseaseKidneyFunctional assaysHomeostasisShift Work and the Risk of Kidney Stones
Knauf F, Luft F, Nath K. Shift Work and the Risk of Kidney Stones. Mayo Clinic Proceedings 2025, 100: 1693-1695. PMID: 41031993, DOI: 10.1016/j.mayocp.2025.08.018.Commentaries, Editorials and LettersUrine Oxalate Excretion and CKD Stage in Patients With Primary Hyperoxaluria Type 1
Vaughan L, Schulte P, Knauf F, Sas D, Milliner D, Lieske J. Urine Oxalate Excretion and CKD Stage in Patients With Primary Hyperoxaluria Type 1. American Journal Of Kidney Diseases 2025, 87: 138-140. PMID: 40983145, PMCID: PMC12462907, DOI: 10.1053/j.ajkd.2025.07.013.Peer-Reviewed Original ResearchClinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman Syndrome
Wieërs M, Allard L, D’Ambrosio V, Arango-Sancho P, de Baaij J, Becherucci F, Bertholet-Thomas A, Besouw M, Blanchard A, Cacciapuoti M, Carbone V, Cornelissen E, Daffara F, Degenhardt J, Devuyst O, Dorresteijn E, Evans R, Figueres L, Fila M, Giliberti M, Gillion V, Haumann S, van der Cingel G, Houillier P, Hureaux M, Knauf F, Knebelmann B, Konrad M, Kwon T, Lemoine S, Longo G, Nijenhuis T, Engberink R, Duro H, Saadé C, Sayer J, Schlingmann K, Simon T, Speeckaert M, Tan H, Trepiccione F, Vargas-Poussou R, Veligratti F, Walsh S, Salih, Silva P, Hoorn E, Study G, Auñón P, Bockenhauer D, Conlon P, Erhardt C, Flammier S, Gómez C, Guven S, Hawkins G, Halbritter J, Herthelius M, Herreros A, Klaric D, Ledó N, Marzuillo P, Schäfer S, Schmitt R, Stanczyk M, Taroni F, Zagorec N. Clinical Characteristics, Symptoms, and Long-Term Outcomes in Gitelman Syndrome. Kidney International Reports 2025, 10: 3967-3983. PMID: 41278357, PMCID: PMC12640036, DOI: 10.1016/j.ekir.2025.09.006.Peer-Reviewed Original ResearchGitelman syndromeChronic kidney diseaseSalt cravingGeneral populationAdult patientsElevated blood cell countsBlood magnesiumPotassium-sparing medicationsRates of albuminuriaRates of chronic kidney diseaseSalt-losing tubulopathyPrevalence of chondrocalcinosisBlood cell countBlood potassium levelsRates of diabetesBlood phosphate levelsClinical characteristicsElectrolyte disordersSymptom burdenClinical dataFemales in adulthoodKidney diseaseMuscle weaknessMuscle crampsSex distributionCoupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits
Scherer N, Fässler D, Borisov O, Cheng Y, Schlosser P, Wuttke M, Haug S, Li Y, Telkämper F, Patil S, Meiselbach H, Wong C, Berger U, Sekula P, Hoppmann A, Schultheiss U, Mozaffari S, Xi Y, Graham R, Schmidts M, Köttgen M, Oefner P, Knauf F, Eckardt K, Grünert S, Estrada K, Thiele I, Hertel J, Köttgen A. Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nature Genetics 2025, 57: 193-205. PMID: 39747595, PMCID: PMC11735408, DOI: 10.1038/s41588-024-01965-7.Peer-Reviewed Original ResearchConceptsWhole-exome sequencing dataGene-metabolite associationsHuman traitsHuman metabolic reactionsSequence dataAllelic seriesGene functionExome sequencingFunctional variantsGenetic studiesInborn errors of metabolismHeterozygous variantsErrors of metabolismMusculoskeletal traitsMetabolic reactionsHuman heightUrine metabolitesHeterozygous stateSulfate reabsorptionInborn errorsTraitsAggregation testVariantsHuman metabolismMetabolomics
2024
Pre-emptive use of glucose 5% as the standard drug solvent reduces hypernatremia in critically ill patients
Hardenberg J, Kunz J, Rubarth K, Mittermaier M, Pigorsch M, Balzer F, Witzenrath M, Hinz R, Körner R, Eckardt K, Knauf F, Hinrichs C, Enghard P. Pre-emptive use of glucose 5% as the standard drug solvent reduces hypernatremia in critically ill patients. Clinical Kidney Journal 2024, 17: sfae328. PMID: 39582778, PMCID: PMC11584513, DOI: 10.1093/ckj/sfae328.Peer-Reviewed Original ResearchGlucose 5% solutionGlucose 5%Severe hypernatremiaDrug diluentDrug solventSodium concentrationAssociated with increased mortalityResults Baseline characteristicsAdult COVID-19 patientsRetrospective before-and-after studyCritically ill patientsIntensive care unitPre-emptive usePrevalence of hypernatremiaStudy intensive care unitVenous blood gasesLength of stayCOVID-19 patientsBaseline characteristicsClinical outcomesICU admissionHypernatremiaMedical ICUCare unitBlood gasesBASELINE CHARACTERISTICS FROM BONAPH1DE: A GLOBAL, OBSERVATIONAL, LONGITUDINAL STUDY OF PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1
Silva¹ R, C² J, Baum³ M, Knauf⁴ F, Verhulst⁵ K, Du¹ W, Brown¹ T, Groothoff⁶ J. BASELINE CHARACTERISTICS FROM BONAPH1DE: A GLOBAL, OBSERVATIONAL, LONGITUDINAL STUDY OF PATIENTS WITH PRIMARY HYPEROXALURIA TYPE 1. 2024, s180-s180. DOI: 10.65034/bjnabstract-cbn240180.Peer-Reviewed Original ResearchPrimary hyperoxaluria type 1Stage 2 chronic kidney diseaseHistory of kidney stonesYear pre-enrollmentKidney stonesNormal kidney functionLongitudinal study of patientsStudy of patientsReal-world safetyHyperoxaluria type 1Systemic oxalosisOxalate overproductionCKD progressionReport historyKidney functionLumasiranNormal kidneyTransplant historyKidney diseaseRare diseasePatientsObservational studyType 1Kidney failureTreatment historyOpportunities in Primary and Enteric Hyperoxaluria at the Cross-Roads Between the Clinic and Laboratory
Cellini B, Baum M, Frishberg Y, Groothoff J, Harris P, Hulton S, Knauf F, Knight J, Lieske J, Lowther W, Moochhala S, Nazzal L, Tasian G, Whittamore J, Sas D. Opportunities in Primary and Enteric Hyperoxaluria at the Cross-Roads Between the Clinic and Laboratory. Kidney International Reports 2024, 9: 3083-3096. PMID: 39534212, PMCID: PMC11551133, DOI: 10.1016/j.ekir.2024.08.031.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPrimäre Hyperoxalurie
Saadé C, Knauf F. Primäre Hyperoxalurie. Nephrologie Aktuell 2024, 28: 272-278. DOI: 10.1055/a-2270-5042.Peer-Reviewed Original ResearchRecovery From Severe Heart Failure in a Patient With Primary Hyperoxaluria Type 1 After Treatment With Lumasiran, Pyridoxine, and Kidney Transplant
Choi M, Kahl A, Hawkins-van der Cingel G, Noriega M, Klingel K, Doeblin P, Schoenrath F, Eckardt K, Öllinger R, Knauf F, Halleck F. Recovery From Severe Heart Failure in a Patient With Primary Hyperoxaluria Type 1 After Treatment With Lumasiran, Pyridoxine, and Kidney Transplant. Annals Of Internal Medicine Clinical Cases 2024, 3 DOI: 10.7326/aimcc.2023.1428.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Get In Touch
Contacts
Email